Navigation Links
Neupro® (Rotigotine) Provided Clinically Relevant Improvements in Health-Related Quality of Life for People with Parkinson's Disease
Date:9/30/2010

BRUSSELS, Sept. 30 /PRNewswire/ -- People with Parkinson's disease who used once-daily Neupro® (rotigotine) in the RECOVER trial achieved improvements in quality of life, in addition to previously reported beneficial effects on motor and non-motor symptoms.

Data presented this week at the 2nd World Parkinson Congress in Glasgow, UK, showed that Neupro® provided clinically relevant improvements in PDQ-8 score. This is a self-administered health-related quality of life questionnaire (HRQL) for Parkinson's disease comprising eight items – mobility, activities of daily living, emotional well-being, social support, cognition, communication, bodily discomfort and stigma.

"Data from the RECOVER trial demonstrated improvements in motor and non-motor symptoms for people living with Parkinson's disease as well as worthwhile changes in the quality of their everyday lives, including their daily activities, their emotional well being and their cognitive and communication abilities," said Herve Lilliu, Head of Health Outcomes and Access, UCB.

The RECOVER trial was a multicenter, multinational, double-blind, placebo-controlled study designed to assess the effects of rotigotine in controlling early morning motor function and non-motor symptoms that affect the everyday lives of people with early- and late-stage Parkinson's disease. Patients were randomized (2:1) to receive rotigotine (2-16 mg/24 h) or placebo during a titration period lasting up to 8 weeks, followed by a 4-week maintenance period.

PDQ-8 data were obtained from measurements taken at baseline and at the end of the 12 week study from 89 placebo- and 176 rotigotine-randomized patients. Mean change from baseline PDQ-8 total score was greater in the rotigotine group (-6.9 [SD: 11.9]) than the placebo group (-1.2 [SD: 13.7]; p<0.001). Both the rotigotine effect size (-0.41) and standardized response mean (-0.58) were moderate based on the Cohen definition of change (0.20 sm
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
2. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
3. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
4. Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI
5. Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study
6. Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009
7. Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
8. Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study
9. Study Data Show INTUNIV™ (guanfacine) Extended Release Tablets Co-administered With Stimulants Provided ADHD Symptom Improvement in Children and Adolescents
10. New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at 52 Weeks
11. New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , April 27, 2015 TWi ... entered into a Settlement Agreement with Takeda Pharmaceutical ... , Inc., Takeda Pharmaceuticals America, Inc. (individually and ... patent litigation related to TWi,s generic dexlansoprazole delayed ... and 60 mg dosage strengths. An Abbreviated New Drug ...
(Date:4/26/2015)... Cancer experts have reported how a Varian ... the area of distributed learning is helping to harness ... patients. Speakers at a Varian-hosted symposium at the 3 ... Barcelona detailed the importance of ... to help benefit the next patient. With ...
(Date:4/25/2015)... BARCELONA, Spain , April 25, 2015  With ... the benefits of precision cranial radiosurgery are now available ... types and sizes. This latest generation stereotactic radiosurgery system ... and imaging technologies, significantly increasing the versatility of Gamma ... at the 3 rd ESTRO Forum in ...
Breaking Medicine Technology:TWi Announces Settlement with Takeda on Dexilant(R) Litigation 2Cancer Experts Detail How 'Big Data' Plays a Critical Role in Improving Clinical Decision-Making in Oncology Treatments at 3rd ESTRO Forum 2Cancer Experts Detail How 'Big Data' Plays a Critical Role in Improving Clinical Decision-Making in Oncology Treatments at 3rd ESTRO Forum 3New Leksell Gamma Knife to benefit more patients with brain disease 2New Leksell Gamma Knife to benefit more patients with brain disease 3
... As a neurologist who has discovered and described medical ... Gazette article "Vets taking Post Traumatic Stress Disorder drugs die ... these unexplained deaths. Andrew White, Eric Layne, ... four West Virginia veterans who died in their sleep in ...
... WARSAW, Ind., Nov. 7, 2011 Zimmer Holdings, ... commenced a $550 million public offering of senior notes. ... of the offering to repay a substantial portion of the ... purposes. Merrill Lynch, Pierce, Fenner & Smith Incorporated, ...
Cached Medicine Technology:Hundreds of Soldiers & Vets Dying From Antipsychotic--Seroquel 2Hundreds of Soldiers & Vets Dying From Antipsychotic--Seroquel 3Zimmer Holdings, Inc. Announces Offering of Senior Notes 2
(Date:4/27/2015)... April 27, 2015 Ticket Down is a ... Philadelphia for his upcoming concert on Sunday, June 21st. ... thrill his countless North American fans again in 2015 when ... his "Out There" tour. He will be performing in ... to listen to this legendary performer for the first time ...
(Date:4/27/2015)... Beckman Coulter is sponsoring a new ... evolution of neural circuitry and swimming behavior of sea ... by which analogous forms of swimming behavior, such as ... in certain sea slug clades. The webinar is free ... 2015 at 8:00am PT. , Sea slugs (Mollusca, Gastropoda, ...
(Date:4/27/2015)... 2015 Thanks to a $7.5 million ... a half-dozen institutions, including American University, will operate in ... social and behavioral research aimed at ending the AIDS ... living with HIV or AIDS, according to the latest ... D.C.'s population over the age of 13 was living ...
(Date:4/27/2015)... NJ (PRWEB) April 27, 2015 As ... security management standard for companies of all sizes and ... leader in helping companies prepare for ISO 27001 certification. ... of clients to prepare them for ISO 27001 certification. ... ever, as evidenced by the number of Lead Implementers ...
(Date:4/27/2015)... Los Angeles, CA (PRWEB) April 27, 2015 ... years has been to connect clients of personal injury attorneys ... The network of doctors has seen steady growth throughout their ... Dr. Charles E. Richardson, DC and his team in ... team including a medical doctor and massage therapist, patients can ...
Breaking Medicine News(10 mins):Health News:Paul McCartney Presale Tickets at Wells Fargo Center in Philadelphia: Ticket Down Slashes Paul McCartney Ticket Prices in Philadelphia at the Wells Fargo Center 2Health News:Beckman Coulter Genomics Presents Using Next-Gen Sequencing to Study the Evolution of Neural Circuitry 2Health News:Beckman Coulter Genomics Presents Using Next-Gen Sequencing to Study the Evolution of Neural Circuitry 3Health News:D.C. Center for AIDS Research Established with New Grant from NIH 2Health News:D.C. Center for AIDS Research Established with New Grant from NIH 3Health News:Six Additional New ISO 27001 Lead Implementers Certified for Pivot Point Security 2Health News:Prominent Doctors with Distinguished Backgrounds Join Doctors on Liens in Tujunga 2
... JOLLA, CA April 14, 2011 An enzyme essential ... way that might be exploited as anti-cancer therapy, say researchers ... The research, published in the April 15, 2011 issue ... group of enzymes called flap endonucleases, which are essential to ...
... Human Vaccine Institute today announced a collaboration and ... enable the rapid development of a vaccine and ... threat such as pandemic influenza. The team, composed ... of the National Institute of Allergy and Infectious ...
... noon ET) The circadian system that controls normal ... brain cells called astrocytes, according to a study published ... a Cell Press publication. Neuroscientists from Tufts University School ... fruit flies (Drosophila) led to altered daily rhythms, an ...
... INDIANAPOLIS With mounting evidence that patient-centered care ... and Indiana University School of Medicine are providing ... future physicians to master relationship skills as well ... 21st Century medicine. "Crossing the ...
... of polluted air appears to activate a protein that ... events that lead to widespread inflammation, according to new ... the gap in researchers, understanding of how prolonged exposure ... and other diseases. The research group, led by ...
... An international consortium of scientists, including major ... the "one-size fits all" strategy of uniformly doubling ... patients with high on-treatment platelet reactivity does not ... stent thrombosis after percutaneous coronary intervention (PCI). The ...
Cached Medicine News:Health News:Study suggests enzyme crucial to DNA replication may provide potent anti-cancer drug target 2Health News:Study suggests enzyme crucial to DNA replication may provide potent anti-cancer drug target 3Health News:Study suggests enzyme crucial to DNA replication may provide potent anti-cancer drug target 4Health News:Duke Human Vaccine Institute signs research agreement to develop pandemic virus vaccines 2Health News:Duke Human Vaccine Institute signs research agreement to develop pandemic virus vaccines 3Health News:Rising star of brain found to regulate circadian rhythms 2Health News:Training future doctors to enlist patients as partners in care 2Health News:Polluted air leads to disease by promoting widespread inflammation 2Health News:Polluted air leads to disease by promoting widespread inflammation 3Health News:Polluted air leads to disease by promoting widespread inflammation 4Health News:Polluted air leads to disease by promoting widespread inflammation 5Health News:Antiplatelets: 1 person, 1 dose? 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: